Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $60
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $50 to $60.
Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $50 to $60.